Abstract
We herein examined the treatment courses of 44 patients diagnosed with severe acute epipharyngitis according to a clinical scoring system for acute tonsillopharyngitis at our healthcare facility during 2015. The patients were treated with garenoxacin (GRNX； 400 mg per day). GRNX was discontinued because of adverse side effects in one patient. A seven-day course of GRNX resulted in resolution of the symptoms in 38 (88%) patients. Regarding adverse drug reactions, a drug rash occurred in 1 patient (2%), however, there were no serious adverse drug reactions. GRNX was not effective in 5 patients, thus necessitating a change in the antimicrobial therapy； Haemophilus parainfluenzae was detected in all 5 patients. GRNX is thus considered to be an effective antibiotic for the treatment of severe acute epipharyngitis.
